Apixaban drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Apixaban Drug Interactions: Key Mechanisms and Clinical Implications
Apixaban Metabolism and Interaction Pathways
Apixaban is primarily metabolized by the liver enzyme CYP3A4 and is also a substrate for the P-glycoprotein (P-gp) transporter. This means that drugs which inhibit or induce CYP3A4 or P-gp can significantly affect apixaban levels in the body, potentially leading to increased risk of bleeding or reduced effectiveness against blood clots 1279.
Pharmacodynamic and Pharmacokinetic Drug Interactions
Pharmacodynamic Interactions
Pharmacodynamic interactions occur when apixaban is combined with other drugs that affect blood clotting, such as antiplatelet agents (like aspirin), non-steroidal anti-inflammatory drugs (NSAIDs), and some antidepressants. These combinations can increase the risk of bleeding events, especially gastrointestinal hemorrhage, which is the most commonly reported adverse reaction 1410.
Pharmacokinetic Interactions
Pharmacokinetic interactions involve changes in how apixaban is absorbed, distributed, metabolized, or excreted. Strong inhibitors of CYP3A4 and P-gp (such as cobicistat, some antitumor drugs, and certain antifungals like fluconazole) can increase apixaban blood levels, raising the risk of bleeding. Conversely, strong inducers (such as primidone and some antiepileptics) can lower apixaban levels, reducing its effectiveness 1235+4 MORE.
Real-World Prevalence and Clinical Outcomes
In real-world settings, nearly half of patients taking apixaban for conditions like non-valvular atrial fibrillation are exposed to potential drug interactions, with most involving other medications that affect blood clotting. About 10% of patients experience interactions that affect how apixaban is processed in the body, mainly due to drugs that inhibit or induce CYP3A4 or P-gp . Some patients are prescribed interacting drugs without a clear clinical need, and inappropriate dosing of apixaban is not uncommon .
Specific Drug Interactions of Note
- Antiplatelet agents and NSAIDs: Increase bleeding risk when combined with apixaban 1410.
- CYP3A4/P-gp inhibitors (e.g., cobicistat, fluconazole, some antitumor drugs): Can significantly increase apixaban levels and bleeding risk 1367+2 MORE.
- CYP3A4/P-gp inducers (e.g., primidone, some antiepileptics): Can decrease apixaban levels, potentially reducing its effectiveness 157.
- Statins and cardiovascular drugs (e.g., amiodarone, diltiazem): May modestly increase apixaban concentrations, but the clinical significance varies .
- Cancer therapies (e.g., adagrasib, asciminib): Can inhibit apixaban metabolism, increasing its blood levels .
Clinical Management and Recommendations
Most drug interactions with apixaban are pharmacodynamic, leading to increased bleeding risk, but pharmacokinetic interactions—especially with strong CYP3A4/P-gp modulators—are also important. Dose adjustments may be necessary when apixaban is used with strong inhibitors, but not always with moderate inhibitors or inducers 278. Regular review of all medications and careful monitoring for signs of bleeding or clotting are essential, especially in patients with multiple comorbidities or those taking many medications 147.
Conclusion
While apixaban generally has a lower risk of drug interactions compared to older anticoagulants, significant interactions can still occur, especially with drugs that affect CYP3A4 or P-gp, or those that also impact blood clotting. Clinicians should always assess for potential drug interactions, adjust doses as needed, and monitor patients closely to ensure safe and effective use of apixaban 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic